Early ERCP in acute biliary pancreatitis

In this non-randomized trial of patients with acute biliary pancreatitis (without cholangitis), patients received either ERCP (within 72 hours) or conservative treatment (at the discretion of the treating physician). Patient characteristics were similar between the groups, and about half received ERCP. The patients were compared in groups by whether or not they had cholestasis (bili>2.3 or common bile duct dilation). Patients with cholestasis had fewer complications with ERCP (adjusted OR=0.35), but there was no significant difference in those without cholestasis. Although not randomized, patients with acute biliary pancreatitis and cholestasis appear to benefit from early ERCP (abstract).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment